PT1408981E - Métodos para prevenção do ganho de peso induzido por antipsicóticos - Google Patents
Métodos para prevenção do ganho de peso induzido por antipsicóticos Download PDFInfo
- Publication number
- PT1408981E PT1408981E PT02750269T PT02750269T PT1408981E PT 1408981 E PT1408981 E PT 1408981E PT 02750269 T PT02750269 T PT 02750269T PT 02750269 T PT02750269 T PT 02750269T PT 1408981 E PT1408981 E PT 1408981E
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- weight gain
- induced weight
- preventing
- receptor antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30769301P | 2001-07-23 | 2001-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1408981E true PT1408981E (pt) | 2008-12-04 |
Family
ID=23190816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02750269T PT1408981E (pt) | 2001-07-23 | 2002-07-22 | Métodos para prevenção do ganho de peso induzido por antipsicóticos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6680310B2 (pt) |
| EP (1) | EP1408981B1 (pt) |
| JP (2) | JP2004537563A (pt) |
| KR (1) | KR20040028942A (pt) |
| CN (2) | CN1547473A (pt) |
| AT (1) | ATE406166T1 (pt) |
| AU (1) | AU2002319665B2 (pt) |
| BR (1) | BR0211365A (pt) |
| CA (1) | CA2454339C (pt) |
| CY (1) | CY1108562T1 (pt) |
| DE (1) | DE60228579D1 (pt) |
| DK (1) | DK1408981T3 (pt) |
| ES (1) | ES2312598T3 (pt) |
| HK (1) | HK1061526A1 (pt) |
| IL (1) | IL159913A0 (pt) |
| MX (1) | MXPA04000692A (pt) |
| NZ (1) | NZ530724A (pt) |
| PT (1) | PT1408981E (pt) |
| WO (1) | WO2003009853A1 (pt) |
| ZA (1) | ZA200400444B (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04001893A (es) * | 2001-08-31 | 2005-03-07 | Corcept Therapeutics Inc | Metodos para inhibir deterioro cognoscitivo en adultos con sindrome de down. |
| NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
| GB0400031D0 (en) | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| US20060211667A1 (en) * | 2005-03-21 | 2006-09-21 | Eric Marchewitz | Use of pregnane steroid derivatives for enhancing physical performance |
| WO2007067714A2 (en) * | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| US8198305B2 (en) * | 2007-04-13 | 2012-06-12 | Concert Pharmaceuticals Inc. | 1,2-benzisoxazol-3-yl compounds |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| CN106029066B (zh) | 2013-11-25 | 2019-03-15 | 科赛普特治疗公司 | 八氢稠合的氮杂萘烷糖皮质激素受体调节剂 |
| US9943526B2 (en) | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
| MX2019011543A (es) | 2017-03-31 | 2019-12-16 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoides para el tratamiento de cancer cervical. |
| WO2018227248A1 (en) * | 2017-06-13 | 2018-12-20 | Monash University | Methods and compositions for the treatment of obesity |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CN113194931B (zh) | 2018-12-19 | 2023-11-10 | 科塞普特治疗公司 | 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂 |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| JP2022523376A (ja) | 2019-02-22 | 2022-04-22 | コーセプト セラピューティクス， インコーポレイテッド | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
| WO2020190351A1 (en) * | 2019-03-18 | 2020-09-24 | Nieman Lynnette K | Method for improving insulin sensitivity |
| JP2023505948A (ja) * | 2019-12-11 | 2023-02-14 | コーセプト セラピューティクス， インコーポレイテッド | 抗精神病薬誘発性体重増加のミリコリラントによる治療方法 |
| JP7474869B2 (ja) | 2020-05-06 | 2024-04-25 | コーセプト セラピューティクス， インコーポレイテッド | ピリミジンシクロヘキシルグルココルチコイド受容体モジュレーターの製剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757400B1 (fr) * | 1996-12-19 | 1999-12-17 | Hoechst Marion Roussel Inc | Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs |
| WO1998027986A1 (en) * | 1996-12-24 | 1998-07-02 | Zymogenetics, Inc. | Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes |
| JP2001518509A (ja) * | 1997-10-06 | 2001-10-16 | ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ | グルココルチコイド関連機能不全に関連した精神病の処置のための方法。 |
| IL139672A (en) | 1998-05-15 | 2005-11-20 | Univ Leland Stanford Junior | Glucocorticoid receptor antagonists for the tretment of dementia |
| JP2003500353A (ja) * | 1999-05-19 | 2003-01-07 | アストラゼネカ・アクチエボラーグ | 処置方法 |
-
2002
- 2002-07-22 IL IL15991302A patent/IL159913A0/xx not_active IP Right Cessation
- 2002-07-22 ES ES02750269T patent/ES2312598T3/es not_active Expired - Lifetime
- 2002-07-22 US US10/201,356 patent/US6680310B2/en not_active Expired - Lifetime
- 2002-07-22 NZ NZ530724A patent/NZ530724A/en not_active IP Right Cessation
- 2002-07-22 KR KR10-2004-7001039A patent/KR20040028942A/ko not_active Application Discontinuation
- 2002-07-22 CA CA2454339A patent/CA2454339C/en not_active Expired - Fee Related
- 2002-07-22 PT PT02750269T patent/PT1408981E/pt unknown
- 2002-07-22 JP JP2003515245A patent/JP2004537563A/ja active Pending
- 2002-07-22 EP EP02750269A patent/EP1408981B1/en not_active Expired - Lifetime
- 2002-07-22 AT AT02750269T patent/ATE406166T1/de active
- 2002-07-22 WO PCT/US2002/023441 patent/WO2003009853A1/en active IP Right Grant
- 2002-07-22 AU AU2002319665A patent/AU2002319665B2/en not_active Ceased
- 2002-07-22 DK DK02750269T patent/DK1408981T3/da active
- 2002-07-22 CN CNA028166647A patent/CN1547473A/zh active Pending
- 2002-07-22 DE DE60228579T patent/DE60228579D1/de not_active Expired - Lifetime
- 2002-07-22 MX MXPA04000692A patent/MXPA04000692A/es active IP Right Grant
- 2002-07-22 BR BR0211365-1A patent/BR0211365A/pt not_active Application Discontinuation
- 2002-07-22 CN CNA2005101236436A patent/CN1853722A/zh active Pending
-
2004
- 2004-01-21 ZA ZA2004/00444A patent/ZA200400444B/en unknown
- 2004-06-21 HK HK04104474A patent/HK1061526A1/xx not_active IP Right Cessation
-
2008
- 2008-11-12 CY CY20081101296T patent/CY1108562T1/el unknown
-
2009
- 2009-02-03 JP JP2009023156A patent/JP2009102413A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2454339A1 (en) | 2003-02-06 |
| EP1408981A1 (en) | 2004-04-21 |
| DK1408981T3 (da) | 2009-01-12 |
| AU2002319665B2 (en) | 2006-09-21 |
| NZ530724A (en) | 2005-09-30 |
| HK1061526A1 (en) | 2004-09-24 |
| CA2454339C (en) | 2012-01-10 |
| ATE406166T1 (de) | 2008-09-15 |
| DE60228579D1 (de) | 2008-10-09 |
| EP1408981B1 (en) | 2008-08-27 |
| KR20040028942A (ko) | 2004-04-03 |
| CY1108562T1 (el) | 2014-04-09 |
| BR0211365A (pt) | 2004-09-21 |
| WO2003009853A1 (en) | 2003-02-06 |
| CN1547473A (zh) | 2004-11-17 |
| ES2312598T3 (es) | 2009-03-01 |
| IL159913A0 (en) | 2004-06-20 |
| MXPA04000692A (es) | 2004-04-21 |
| ZA200400444B (en) | 2005-03-30 |
| CN1853722A (zh) | 2006-11-01 |
| JP2009102413A (ja) | 2009-05-14 |
| US20030027802A1 (en) | 2003-02-06 |
| JP2004537563A (ja) | 2004-12-16 |
| US6680310B2 (en) | 2004-01-20 |
| EP1408981A4 (en) | 2005-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108562T1 (el) | Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες | |
| IL139672A (en) | Glucocorticoid receptor antagonists for the tretment of dementia | |
| WO2002076390A3 (en) | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists | |
| CA2302586A1 (en) | Methods for treating psychosis associated with glucocorticoid related dysfunction | |
| WO2004058717A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| HK1068783A1 (en) | Methods for increasing the therapeutic response to electroconvulsive therapy ("ect") | |
| TR200301613T2 (tr) | Sapogenin türevleri, bunların sentezi ve kullanımı, bunların kullanım metotları. | |
| AU2003256410A8 (en) | Combination therapy with p38 map kinase inhibitors and their pharmaceutical compositions | |
| IL160649A0 (en) | Methods for inhibiting cognitive deterioration in adults with down syndrome | |
| TWI318879B (en) | Powdered mixture of plant sterol and emulsifier and preparation thereof | |
| CA2389570A1 (en) | Methods for treating mild cognitive impairment | |
| MXPA01008993A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
| WO2004069202A3 (en) | Antiglucocorticoids for the treatment of postpartum psychosis | |
| IL158744A0 (en) | Methods for treating delirium using glucocorticoid receptor-specific antagonists | |
| AU2003231019A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING Alpha3Beta4 NICOTINIC RECEPTOR ANTAGONISTS AND METHODS OF THEIR USE | |
| NO20023841D0 (no) | Anvendelse av glukokortikoidreseptorantagonister for forebygging og behandling av sykdommer av reproduksjonssystemethos menn | |
| IL149357A0 (en) | Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents | |
| DK1165184T3 (da) | Estrogenreceptor-beta antagonisme og knoglesygdomme | |
| EP1726307A3 (en) | Methods for treating psychosis associated with glucocorticoid related dysfunction | |
| AU2002219192A1 (en) | Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect |